A detailed history of Ubs Group Ag transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 69,316 shares of TARS stock, worth $3.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,316
Previous 27,973 147.8%
Holding current value
$3.81 Million
Previous $760,000 199.87%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.54 - $34.6 $890,528 - $1.43 Million
41,343 Added 147.8%
69,316 $2.28 Million
Q2 2024

Aug 13, 2024

SELL
$25.17 - $38.73 $260,937 - $401,513
-10,367 Reduced 27.04%
27,973 $760,000
Q1 2024

May 13, 2024

BUY
$19.61 - $39.22 $153,879 - $307,759
7,847 Added 25.73%
38,340 $1.39 Million
Q4 2023

Feb 09, 2024

BUY
$12.98 - $20.73 $149,166 - $238,229
11,492 Added 60.48%
30,493 $617,000
Q3 2023

Nov 09, 2023

BUY
$14.75 - $24.62 $22,700 - $37,890
1,539 Added 8.81%
19,001 $337,000
Q2 2023

Aug 11, 2023

BUY
$11.57 - $19.63 $108,815 - $184,620
9,405 Added 116.73%
17,462 $315,000
Q1 2023

May 12, 2023

BUY
$11.92 - $16.27 $14,292 - $19,507
1,199 Added 17.48%
8,057 $101,000
Q4 2022

Feb 08, 2023

BUY
$14.12 - $18.72 $86,950 - $115,277
6,158 Added 879.71%
6,858 $100,000
Q2 2022

Aug 10, 2022

SELL
$11.08 - $19.08 $39,068 - $67,276
-3,526 Reduced 83.44%
700 $10,000
Q1 2022

May 16, 2022

BUY
$14.49 - $24.28 $16,547 - $27,727
1,142 Added 37.03%
4,226 $71,000
Q4 2021

Feb 14, 2022

BUY
$21.21 - $29.68 $54,806 - $76,693
2,584 Added 516.8%
3,084 $70,000
Q3 2021

Nov 15, 2021

BUY
$21.45 - $29.22 $10,725 - $14,610
500 New
500 $11,000
Q2 2021

Aug 13, 2021

SELL
$27.16 - $38.59 $67,791 - $96,320
-2,496 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$27.37 - $47.25 $32,050 - $55,329
1,171 Added 88.38%
2,496 $80,000
Q4 2020

Feb 11, 2021

BUY
$19.17 - $49.62 $25,400 - $65,746
1,325 New
1,325 $55,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.47B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.